Chiron Deal Offers Novartis Entry Into Vaccine Business
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis seeks to acquire remaining 57.8% of Chiron it does not already own with an all-cash bid of $4.5 bil.
You may also be interested in...
Novartis Willing To “Walk Away” From Chiron Bid
Chiron’s business is “strategically attractive,” but the company faces several challenges, particularly in vaccine manufacturing, Novartis CEO Vasella says.
Novartis Willing To “Walk Away” From Chiron Bid
Chiron’s business is “strategically attractive,” but the company faces several challenges, particularly in vaccine manufacturing, Novartis CEO Vasella says.
Chiron Seeking To Bump Up Buyout Bid? Directors Reject Novartis’ Offer
A $4.5 bil. cash offer from Novartis for an outstanding 57.8% stake in Chiron is “inadequate,” according to Chiron’s independent directors.